OpenMedicare
Start Here
Explore
Fraud
Investigations
Data
Tools
About

Footer

OpenMedicare

Independent Medicare data journalism

Sister Sites

  • OpenMedicaid
  • OpenFeds
  • OpenSpending

Explore

  • Providers
  • Procedures
  • States
  • Specialties
  • Search

Fraud Analysis

  • Still Out There (AI)
  • Fraud Overview
  • Fraud Watchlist
  • Deep Dive Profiles
  • Impossible Numbers
  • Report Fraud

Investigations

  • The Algorithm Knows
  • How We Built the Model
  • Internal Medicine Crisis
  • Florida & California Fraud
  • Million Dollar Flagged
  • All Investigations

Tools

  • Provider Lookup
  • Compare
  • Cost Calculator
  • Your Medicare Dollar
  • Downloads

About

  • About OpenMedicare
  • Methodology
  • Glossary
  • Data Sources
  • API Docs
  • Updates
Data Sources: Centers for Medicare & Medicaid Services (CMS), Medicare Provider Utilization and Payment Data
Disclaimer: This site is an independent journalism project. Data analysis and editorial content are not affiliated with or endorsed by CMS or any government agency. All spending figures are based on publicly available Medicare payment records.
Sister Sites: OpenMedicaid ยท OpenFeds ยท OpenSpending

ยฉ 2026 OpenMedicare. Independent data journalism. Built by TheDataProject.ai

Methodologyโ€ขDownload Data
  1. Home
  2. Providers
  3. Thomas Buroker
๐ŸŽ—๏ธ
DOIndividual

Thomas Buroker, DO

NPI: 1982665337
Des Moines, IA
10 years of data
Medical Oncology
$44.4M
Total Payments
437
Beneficiaries
2.7M
Services
2.39x
Markup Ratio

Peer Comparison

99th
percentile in specialty
This provider$44.4M
Specialty median$262.8K
Rank #5 of 17 in specialty

๐Ÿ“‹ Key Findings

1Billed $44.4M over 10 years
22.39x markup ratio (above median)
399th percentile in Medical Oncology by payments
41.1K services/day โ€” physically implausible
5Payments surged 247% in 2019
63 procedures with >3x markup

โš ๏ธ This provider averages 1.1K services per working day โ€” physically unusual for an individual practitioner

Based on 2.7M total services over 10 years (250 working days/year). Learn about impossible service volumes โ†’

๐Ÿ”Ž Data Analysis

This provider's $44.4M in total Medicare payments ranks in the 99th percentile of Medical Oncology providers nationally.

Averaging 1.1K services per working day raises questions about billing patterns.

Medicare payments to this provider grew 1191% from 2014 to 2023.

AI-generated analysis based on Medicare payment data.

Annual Medicare Payments

Annual Services Provided

Avg Payment per Service

Markup Ratio Over Time

๐Ÿ“ˆ

Notable: Payments increased 247% in 2019

Year-over-year payment surges can indicate changes in practice volume, new services, or billing pattern shifts.

Submitted Charges vs. Medicare Payments

Average per-service amounts submitted by the provider compared to what Medicare actually paid โ€” the gap represents the markup.

YearAvg SubmittedAvg PaidMarkup RatioGap per ServiceTotal PaymentsServicesBeneficiaries
2014$90.91$40.242.26x$50.67$725.4K18.0K28
2015$61.95$23.822.60x$38.13$358.2K15.0K31
2016$38.15$15.332.49x$22.82$878.3K57.3K33
2017$43.57$18.192.40x$25.38$1.1M59.9K36
2018$57.97$26.202.21x$31.77$1.6M62.6K31
2019$30.45$14.462.11x$15.99$5.7M394.0K52
2020$39.58$16.092.46x$23.49$5.6M351.1K54
2021$39.24$16.382.40x$22.86$8.9M543.5K56
2022$39.54$17.012.32x$22.53$10.0M590.8K60
2023$42.60$16.222.63x$26.38$9.4M577.3K56

Top Procedures (20)

J9271Injection, pembrolizumab, 1 mg
$14.1M
347.6K services$40.67/svc2.14x markup
J9299Injection, nivolumab, 1 mg
$4.7M
220.7K services$21.37/svc2.08x markup
J2505Injection, pegfilgrastim, 6 mg
$2.3M
773 services$3.0K/svc2.34x markup
J9144Injection, daratumumab, 10 mg and hyaluronidase-fihj
$2.1M
57.8K services$37.11/svc1.89x markup
J1930Injection, lanreotide, 1 mg
$1.8M
35.2K services$49.84/svc2.25x markup
J0897Injection, denosumab, 1 mg
$1.6M
108.5K services$15.09/svc2.23x markup
J9173Injection, durvalumab, 10 mg
$1.4M
21.9K services$61.59/svc1.97x markup
J9355Injection, trastuzumab, excludes biosimilar, 10 mg
$1.1M
14.2K services$75.97/svc2.16x markup
96413Administration of chemotherapy into vein, 1 hour or lessโš  3.5x markup
$1.0M
10.1K services$99.00/svc3.52x markup
J9305Injection, pemetrexed, not otherwise specified, 10 mg
$946.3K
17.0K services$55.60/svc2.03x markup
99214Established patient office or other outpatient visit, 30-39 minutes
$945.4K
12.3K services$77.12/svc2.71x markup
J1569Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg
$912.8K
25.8K services$35.45/svc2.34x markup
J9035Injection, bevacizumab, 10 mg
$884.6K
14.6K services$60.63/svc2.26x markup
J9022Injection, atezolizumab, 10 mg
$766.0K
13.8K services$55.41/svc2.10x markup
Q5118Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mgโš  3.2x markup
$713.3K
21.4K services$33.27/svc3.18x markup
J9264Injection, paclitaxel protein-bound particles, 1 mg
$706.2K
67.5K services$10.46/svc2.17x markup
J9041Injection, bortezomib (velcade), 0.1 mg
$689.0K
19.5K services$35.39/svc2.13x markup
Q5112Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mgโš  3.0x markup
$537.3K
11.0K services$48.72/svc3.02x markup
J9312Injection, rituximab, 10 mg
$445.9K
6.0K services$74.34/svc2.11x markup
99233Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
$432.1K
5.5K services$78.33/svc2.50x markup
Show detailed table โ–พ
CodeDescriptionServicesPaymentsAvg/ServiceMarkup
J9271Injection, pembrolizumab, 1 mg347.6K$14.1M$40.672.14x
J9299Injection, nivolumab, 1 mg220.7K$4.7M$21.372.08x
J2505Injection, pegfilgrastim, 6 mg773$2.3M$3.0K2.34x
J9144Injection, daratumumab, 10 mg and hyaluronidase-fihj57.8K$2.1M$37.111.89x
J1930Injection, lanreotide, 1 mg35.2K$1.8M$49.842.25x
J0897Injection, denosumab, 1 mg108.5K$1.6M$15.092.23x
J9173Injection, durvalumab, 10 mg21.9K$1.4M$61.591.97x
J9355Injection, trastuzumab, excludes biosimilar, 10 mg14.2K$1.1M$75.972.16x
96413Administration of chemotherapy into vein, 1 hour or less10.1K$1.0M$99.003.52x
J9305Injection, pemetrexed, not otherwise specified, 10 mg17.0K$946.3K$55.602.03x
99214Established patient office or other outpatient visit, 30-39 minutes12.3K$945.4K$77.122.71x
J1569Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg25.8K$912.8K$35.452.34x
J9035Injection, bevacizumab, 10 mg14.6K$884.6K$60.632.26x
J9022Injection, atezolizumab, 10 mg13.8K$766.0K$55.412.10x
Q5118Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg21.4K$713.3K$33.273.18x
J9264Injection, paclitaxel protein-bound particles, 1 mg67.5K$706.2K$10.462.17x
J9041Injection, bortezomib (velcade), 0.1 mg19.5K$689.0K$35.392.13x
Q5112Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg11.0K$537.3K$48.723.02x
J9312Injection, rituximab, 10 mg6.0K$445.9K$74.342.11x
99233Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes5.5K$432.1K$78.332.50x

Markup Analysis

Charge-to-Payment Ratio

2.39x

This provider submits charges 2.39 times higher than what Medicare actually pays.

What This Means

A markup ratio of 2.39x means for every $100 Medicare pays, this provider initially charges $239. This is higher than the national average.

Location

Des Moines, IA

Provider Verification

Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.

Similar Providers

Other Medical Oncology providers in IA for peer comparison.

Thomas Buroker (you)
$44.4M
Robert Behrens, MD
$33.7M
Show detailed table โ–พ
ProviderLocationTotal PaymentsStatus
Robert Behrens, MDDes Moines, IA$33.7Mโœ“ Clear

Related

Browse
โ† Back to Provider Directory
State
All providers in IA โ†’
Specialty
All Medical Oncology providers โ†’
Tool
Compare this provider โ†’
Analysis
Fraud Watchlist โ†’
Search
Search all providers โ†’

Share This Provider

Share this provider's Medicare payment information

Share:

Data Sources

  • โ€ข Centers for Medicare & Medicaid Services (CMS)
  • โ€ข Medicare Provider Utilization and Payment Data (2014-2023)
  • โ€ข National Plan and Provider Enumeration System (NPPES)

Last Updated: February 2026 (data through 2023, the latest CMS release)

Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.

Believe this data is inaccurate? Dispute this data